307 related articles for article (PubMed ID: 30378541)
1. Increased HMGB1 levels in lesional skin and sera in patients with cutaneous T-cell lymphoma.
Senda N; Miyagaki T; Kamijo H; Nakajima R; Oka T; Takahashi N; Suga H; Yoshizaki A; Asano Y; Sugaya M; Sato S
Eur J Dermatol; 2018 Oct; 28(5):621-627. PubMed ID: 30378541
[TBL] [Abstract][Full Text] [Related]
2. Increased CCL18 expression in patients with cutaneous T-cell lymphoma: association with disease severity and prognosis.
Miyagaki T; Sugaya M; Suga H; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e60-7. PubMed ID: 22404649
[TBL] [Abstract][Full Text] [Related]
3. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma.
Sugaya M; Miyagaki T; Ohmatsu H; Suga H; Kai H; Kamata M; Fujita H; Asano Y; Tada Y; Kadono T; Okochi H; Sato S
J Dermatol Sci; 2012 Oct; 68(1):45-51. PubMed ID: 22884782
[TBL] [Abstract][Full Text] [Related]
4. Angiogenin levels are increased in lesional skin and sera in patients with erythrodermic cutaneous T cell lymphoma.
Miyagaki T; Sugaya M; Suga H; Akamata K; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Arch Dermatol Res; 2012 Jul; 304(5):401-6. PubMed ID: 22526325
[TBL] [Abstract][Full Text] [Related]
5. Expression of interleukin-18 and caspase-1 in cutaneous T-cell lymphoma.
Yamanaka K; Clark R; Dowgiert R; Hurwitz D; Shibata M; Rich BE; Hirahara K; Jones DA; Eapen S; Mizutani H; Kupper TS
Clin Cancer Res; 2006 Jan; 12(2):376-82. PubMed ID: 16428475
[TBL] [Abstract][Full Text] [Related]
6. BAFF levels are increased in lesional skin and sera in patients with cutaneous T-cell lymphoma.
Ohmatsu H; Sugaya M; Miyagaki T; Suga H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Br J Dermatol; 2012 Aug; 167(2):359-67. PubMed ID: 22512719
[TBL] [Abstract][Full Text] [Related]
7. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma.
Miyagaki T; Sugaya M; Suga H; Kamata M; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Clin Cancer Res; 2011 Dec; 17(24):7529-38. PubMed ID: 22048239
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
[TBL] [Abstract][Full Text] [Related]
9. Association of nerve growth factor, chemokine (C-C motif) ligands and immunoglobulin E with pruritus in cutaneous T-cell lymphoma.
Suga H; Sugaya M; Miyagaki T; Ohmatsu H; Fujita H; Kagami S; Asano Y; Tada Y; Kadono T; Sato S
Acta Derm Venereol; 2013 Mar; 93(2):144-9. PubMed ID: 22948508
[TBL] [Abstract][Full Text] [Related]
10. Serological immunomarkers in cutaneous T cell lymphoma.
Hassel JC; Meier R; Joller-Jemelka H; Burg G; Dummer R
Dermatology; 2004; 209(4):296-300. PubMed ID: 15539892
[TBL] [Abstract][Full Text] [Related]
11. Increased Interleukin-19 Expression in Cutaneous T-cell Lymphoma and Atopic Dermatitis.
Oka T; Sugaya M; Takahashi N; Nakajima R; Otobe S; Kabasawa M; Suga H; Miyagaki T; Asano Y; Sato S
Acta Derm Venereol; 2017 Nov; 97(10):1172-1177. PubMed ID: 28597022
[TBL] [Abstract][Full Text] [Related]
12. A distinct profile of serum levels of soluble intercellular adhesion molecule-1 and intercellular adhesion molecule-3 in mycosis fungoides and Sézary syndrome.
López-Lerma I; Estrach MT
J Am Acad Dermatol; 2009 Aug; 61(2):263-70. PubMed ID: 19615537
[TBL] [Abstract][Full Text] [Related]
13. Eotaxins and CCR3 interaction regulates the Th2 environment of cutaneous T-cell lymphoma.
Miyagaki T; Sugaya M; Fujita H; Ohmatsu H; Kakinuma T; Kadono T; Tamaki K; Sato S
J Invest Dermatol; 2010 Sep; 130(9):2304-11. PubMed ID: 20505746
[TBL] [Abstract][Full Text] [Related]
14. Low herpesvirus entry mediator (HVEM) expression on dermal fibroblasts contributes to a Th2-dominant microenvironment in advanced cutaneous T-cell lymphoma.
Miyagaki T; Sugaya M; Suga H; Morimura S; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
J Invest Dermatol; 2012 Apr; 132(4):1280-9. PubMed ID: 22297640
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-25 is involved in cutaneous T-cell lymphoma progression by establishing a T helper 2-dominant microenvironment.
Nakajima R; Miyagaki T; Hirakawa M; Oka T; Takahashi N; Suga H; Yoshizaki A; Fujita H; Asano Y; Sugaya M; Sato S
Br J Dermatol; 2018 Jun; 178(6):1373-1382. PubMed ID: 29238954
[TBL] [Abstract][Full Text] [Related]
16. Skin barrier dysfunction and low antimicrobial peptide expression in cutaneous T-cell lymphoma.
Suga H; Sugaya M; Miyagaki T; Ohmatsu H; Kawaguchi M; Takahashi N; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Clin Cancer Res; 2014 Aug; 20(16):4339-48. PubMed ID: 24919568
[TBL] [Abstract][Full Text] [Related]
17. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
Wang Y; Gu X; Li W; Zhang Q; Zhang C
J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
[TBL] [Abstract][Full Text] [Related]
18. TOX expression in different subtypes of cutaneous lymphoma.
Morimura S; Sugaya M; Suga H; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Arch Dermatol Res; 2014 Nov; 306(9):843-9. PubMed ID: 25216799
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Significance of Serum Copper in Patients With Cutaneous T-cell Lymphoma.
Vonderheid EC; Martinez AR
Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):228-238.e4. PubMed ID: 30745139
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction.
Gibson JF; Huang J; Liu KJ; Carlson KR; Foss F; Choi J; Edelson R; Hussong JW; Mohl R; Hill S; Girardi M
J Am Acad Dermatol; 2016 May; 74(5):870-7. PubMed ID: 26874819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
